Thioctic acid and glucose metabolism: Studies using insulin-resistant skeletal muscle of the fatty Zucker rat

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Insulin resistance of skeletal muscle glucose metabolism underlies numerous pathological conditions, most notably non-insulin-dependent diabetes mellitus, but also conditions of hyperinsulinemia associated with hypertension, dyslipidemia, and central adiposity ('syndrome X' or the 'insulin resistance syndrome'). Thioctic acid (TA) has been used to treat diabetic polyneuropathy and recent clinical evidence indicates that it may also be effective in increasing insulin-mediated glucose disposal in insulin-resistant humans. The information presented in this brief review article summarizes our recent efforts in identifying a possible cellular site of action for this beneficial effect of TA. To this end, we have investigated the effects of chronic parenteral TA treatment on in vitro glucose metabolism in the epitrochlearis muscle of a well-established animal model of severe insulin resistance, hyperinsulinemia, dyslipidemia, and central obesity: the fatty Zucker rat. Fatty Zucker rats were chronically treated intraperitoneally with vehicle or a racemic mixture of TA (30 mg/kg body weight/day for 10 days). Chronic TA treatment maximally increased insulin-stimulated glucose transport by 29% and both insulin-stimulated glucose oxidation (+35%) and glycogen synthesis (+22%) (all p < 0.05). In vivo glycogen levels were 21% greater (p < 0.05) in muscle from the TA-treated animals. Collectively, these studies indicate that, in this animal model of severe insulin resistance, the primary sites of the beneficial action of TA are the skeletal muscle glucose transport system and both the non-oxidative and oxidative glucose metabolism systems.

Original languageEnglish (US)
Pages (from-to)46-49
Number of pages4
JournalDiabetes und Stoffwechsel
Volume5
Issue number3 SUPPL.
StatePublished - 1996

Fingerprint

Zucker Rats
Thioctic Acid
Skeletal Muscle
Insulin
Glucose
Insulin Resistance
Hyperinsulinism
Dyslipidemias
Glycogen
Animal Models
Metabolic Syndrome X
Muscles
Abdominal Obesity
Diabetic Neuropathies
Adiposity
Type 2 Diabetes Mellitus
Body Weight
Hypertension
Therapeutics

Keywords

  • insulin resistance
  • skeletal muscle
  • thioctic acid
  • Zucker rat

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

@article{371137425501475fa16311bb43836345,
title = "Thioctic acid and glucose metabolism: Studies using insulin-resistant skeletal muscle of the fatty Zucker rat",
abstract = "Insulin resistance of skeletal muscle glucose metabolism underlies numerous pathological conditions, most notably non-insulin-dependent diabetes mellitus, but also conditions of hyperinsulinemia associated with hypertension, dyslipidemia, and central adiposity ('syndrome X' or the 'insulin resistance syndrome'). Thioctic acid (TA) has been used to treat diabetic polyneuropathy and recent clinical evidence indicates that it may also be effective in increasing insulin-mediated glucose disposal in insulin-resistant humans. The information presented in this brief review article summarizes our recent efforts in identifying a possible cellular site of action for this beneficial effect of TA. To this end, we have investigated the effects of chronic parenteral TA treatment on in vitro glucose metabolism in the epitrochlearis muscle of a well-established animal model of severe insulin resistance, hyperinsulinemia, dyslipidemia, and central obesity: the fatty Zucker rat. Fatty Zucker rats were chronically treated intraperitoneally with vehicle or a racemic mixture of TA (30 mg/kg body weight/day for 10 days). Chronic TA treatment maximally increased insulin-stimulated glucose transport by 29{\%} and both insulin-stimulated glucose oxidation (+35{\%}) and glycogen synthesis (+22{\%}) (all p < 0.05). In vivo glycogen levels were 21{\%} greater (p < 0.05) in muscle from the TA-treated animals. Collectively, these studies indicate that, in this animal model of severe insulin resistance, the primary sites of the beneficial action of TA are the skeletal muscle glucose transport system and both the non-oxidative and oxidative glucose metabolism systems.",
keywords = "insulin resistance, skeletal muscle, thioctic acid, Zucker rat",
author = "Henriksen, {Erik J}",
year = "1996",
language = "English (US)",
volume = "5",
pages = "46--49",
journal = "Diabetes und Stoffwechsel",
issn = "1861-7603",
publisher = "Verlag Kirchheim and Co. GmbH",
number = "3 SUPPL.",

}

TY - JOUR

T1 - Thioctic acid and glucose metabolism

T2 - Studies using insulin-resistant skeletal muscle of the fatty Zucker rat

AU - Henriksen, Erik J

PY - 1996

Y1 - 1996

N2 - Insulin resistance of skeletal muscle glucose metabolism underlies numerous pathological conditions, most notably non-insulin-dependent diabetes mellitus, but also conditions of hyperinsulinemia associated with hypertension, dyslipidemia, and central adiposity ('syndrome X' or the 'insulin resistance syndrome'). Thioctic acid (TA) has been used to treat diabetic polyneuropathy and recent clinical evidence indicates that it may also be effective in increasing insulin-mediated glucose disposal in insulin-resistant humans. The information presented in this brief review article summarizes our recent efforts in identifying a possible cellular site of action for this beneficial effect of TA. To this end, we have investigated the effects of chronic parenteral TA treatment on in vitro glucose metabolism in the epitrochlearis muscle of a well-established animal model of severe insulin resistance, hyperinsulinemia, dyslipidemia, and central obesity: the fatty Zucker rat. Fatty Zucker rats were chronically treated intraperitoneally with vehicle or a racemic mixture of TA (30 mg/kg body weight/day for 10 days). Chronic TA treatment maximally increased insulin-stimulated glucose transport by 29% and both insulin-stimulated glucose oxidation (+35%) and glycogen synthesis (+22%) (all p < 0.05). In vivo glycogen levels were 21% greater (p < 0.05) in muscle from the TA-treated animals. Collectively, these studies indicate that, in this animal model of severe insulin resistance, the primary sites of the beneficial action of TA are the skeletal muscle glucose transport system and both the non-oxidative and oxidative glucose metabolism systems.

AB - Insulin resistance of skeletal muscle glucose metabolism underlies numerous pathological conditions, most notably non-insulin-dependent diabetes mellitus, but also conditions of hyperinsulinemia associated with hypertension, dyslipidemia, and central adiposity ('syndrome X' or the 'insulin resistance syndrome'). Thioctic acid (TA) has been used to treat diabetic polyneuropathy and recent clinical evidence indicates that it may also be effective in increasing insulin-mediated glucose disposal in insulin-resistant humans. The information presented in this brief review article summarizes our recent efforts in identifying a possible cellular site of action for this beneficial effect of TA. To this end, we have investigated the effects of chronic parenteral TA treatment on in vitro glucose metabolism in the epitrochlearis muscle of a well-established animal model of severe insulin resistance, hyperinsulinemia, dyslipidemia, and central obesity: the fatty Zucker rat. Fatty Zucker rats were chronically treated intraperitoneally with vehicle or a racemic mixture of TA (30 mg/kg body weight/day for 10 days). Chronic TA treatment maximally increased insulin-stimulated glucose transport by 29% and both insulin-stimulated glucose oxidation (+35%) and glycogen synthesis (+22%) (all p < 0.05). In vivo glycogen levels were 21% greater (p < 0.05) in muscle from the TA-treated animals. Collectively, these studies indicate that, in this animal model of severe insulin resistance, the primary sites of the beneficial action of TA are the skeletal muscle glucose transport system and both the non-oxidative and oxidative glucose metabolism systems.

KW - insulin resistance

KW - skeletal muscle

KW - thioctic acid

KW - Zucker rat

UR - http://www.scopus.com/inward/record.url?scp=0030485459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030485459&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0030485459

VL - 5

SP - 46

EP - 49

JO - Diabetes und Stoffwechsel

JF - Diabetes und Stoffwechsel

SN - 1861-7603

IS - 3 SUPPL.

ER -